KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Payables (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Payables data on record, last reported at $20.8 million in Q4 2025.

  • For Q4 2025, Payables rose 25.2% year-over-year to $20.8 million; the TTM value through Dec 2025 reached $20.8 million, up 25.2%, while the annual FY2025 figure was $20.8 million, 25.2% up from the prior year.
  • Payables reached $20.8 million in Q4 2025 per PACB's latest filing, up from $16.4 million in the prior quarter.
  • Across five years, Payables topped out at $21.0 million in Q1 2024 and bottomed at $3.5 million in Q1 2021.
  • Average Payables over 5 years is $14.0 million, with a median of $15.1 million recorded in 2023.
  • Peak YoY movement for Payables: crashed 35.97% in 2021, then surged 407.26% in 2022.
  • A 5-year view of Payables shows it stood at $11.0 million in 2021, then skyrocketed by 30.23% to $14.3 million in 2022, then increased by 5.12% to $15.1 million in 2023, then rose by 10.14% to $16.6 million in 2024, then grew by 25.2% to $20.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $20.8 million in Q4 2025, $16.4 million in Q3 2025, and $15.1 million in Q2 2025.